TG Ther­a­peu­tic­s' shares jump as um­bral­is­ib wins FDA's break­through sta­tus

7 years ago
Pharma

Ed­i­tas founder Ka­trine Bosley abrupt­ly steps aside from the helm, just ahead of his­toric CRISPR move

7 years ago
People

Cam­bridge spin­out grabs $23M round to launch a new cam­paign to tack­le pro­tein mis­fold­ing

7 years ago
Financing
Startups

FDA slaps a clin­i­cal hold on mes­sen­ger RNA pro­gram for rare ge­net­ic dis­ease

7 years ago
Pharma

Chi­nese gov­ern­ment probe con­demns Jiankui He as rogue sci­en­tist pur­su­ing 'il­le­gal' work on gene-edit­ed ba­bies

7 years ago
China

Au­rinia eye drug falls short in im­prov­ing tol­er­a­bil­i­ty ver­sus Resta­sis, but beats on ef­fi­ca­cy

7 years ago
R&D

Ab­b­Vie, J&J con­cede a fail­ure for block­buster Im­bru­vi­ca in their PhI­II shot at pan­cre­at­ic can­cer

7 years ago
R&D

Tyme flops on can­cer drug da­ta; Lil­ly IND fil­ing trig­gers $8M pay­ment to part­ner Zymeworks

7 years ago
News Briefing

John Mendlein leaves Mod­er­na for Flag­ship; Paul Sekhri to steer first xeno­trans­plan­ta­tion tri­als as eGe­n­e­sis CEO

7 years ago
Peer Review

Cel­gene's top 20 up­front hits: Just how gen­er­ous was Cel­gene in deal­mak­ing? Let's re­view the records

7 years ago
Pharma

Safe­ty con­cerns lead to a split FDA pan­el vote on Sanofi/Lex­i­con di­a­betes drug

7 years ago
R&D
Pharma

Lil­ly's ap­proved can­cer drug Lartru­vo fails con­fir­ma­to­ry study, set­ting the stage for with­draw­al of reg­u­la­to­ry ...

7 years ago
R&D

Cel­gene inks first deals since Bris­tol-My­ers an­nounced $74B buy­out — bets $80M on im­munome­tab­o­lism

7 years ago
Pharma

Im­munomedics must en­dure an­oth­er de­lay as FDA re­jects can­cer drug cit­ing man­u­fac­tur­ing is­sues

7 years ago
R&D

No­var­tis teams up with Ox­ford re­searchers to crunch big da­ta in­to clin­i­cal in­sights

7 years ago
AI

Scoop: For­ma ax­es dis­cov­ery bi­ol­o­gy team as part of a broad­er re­or­ga­ni­za­tion

7 years ago
R&D
Pharma

With J&J deal to as­sess val­ue of Ap­ple watch in atri­al fib­ril­la­tion, tech gi­ant for­ti­fies its for­ay in­to health­care

7 years ago
Pharma

NIH re­searchers re­port an­i­mal mod­el val­i­da­tion for stem cell-based ap­proach to ad­vanced dry AMD

7 years ago
Discovery

Bay­er ax­ing 665 work­ers at US cam­pus; NASH biotech pumps up share price with an ‘in­ter­im’ snap­shot

7 years ago
News Briefing

Look­ing to make a splash at JP­Mor­gan, Eli Lil­ly rushed to put its $8B buy­out deal to­geth­er for Loxo in 10 days

7 years ago
Pharma

Zaf­gen has some­thing to cheer as di­a­betes drug makes the cut in PhII study

7 years ago
R&D

Short sell­er Cit­ron draws fresh blood go­ing af­ter an­oth­er biotech scalp — but can it still cut that deep?

7 years ago
Bioregnum
Opinion

Alzheon hits an­oth­er dead end fund­ing its Alzheimer's pro­gram, pulls sec­ond IPO at­tempt

7 years ago
Financing
R&D

Sec­ond time's a charm for os­teo­poro­sis drug from Am­gen, UCB as FDA pan­el grants its bless­ing

7 years ago
R&D
First page Previous page 981982983984985986987 Next page Last page
A service from the Financial Times